Acticor Biotech SAS
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Pha… Read more
Acticor Biotech SAS (ALACT) - Total Assets
Latest total assets as of June 2024: €10.22 Million EUR
Based on the latest financial reports, Acticor Biotech SAS (ALACT) holds total assets worth €10.22 Million EUR as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Acticor Biotech SAS - Total Assets Trend (2007–2023)
This chart illustrates how Acticor Biotech SAS’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Acticor Biotech SAS - Asset Composition Analysis
Current Asset Composition (December 2023)
Acticor Biotech SAS's total assets of €10.22 Million consist of 95.3% current assets and 4.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 40.0% |
| Accounts Receivable | €4.38 Million | 45.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2007–2023)
This chart illustrates how Acticor Biotech SAS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acticor Biotech SAS's current assets represent 95.3% of total assets in 2023, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 40.0% of total assets in 2023, up from 8.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 53.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 45.1% of total assets.
Acticor Biotech SAS Competitors by Total Assets
Key competitors of Acticor Biotech SAS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Acticor Biotech SAS - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Acticor Biotech SAS generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Acticor Biotech SAS is currently not profitable relative to its asset base.
Acticor Biotech SAS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.85 | 1.52 | 2.89 |
| Quick Ratio | 0.85 | 1.52 | 2.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-1.71 Million | € 4.43 Million | € 1.36 Million |
Acticor Biotech SAS - Advanced Valuation Insights
This section examines the relationship between Acticor Biotech SAS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 18.20 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -24.9% |
| Total Assets | €9.72 Million |
| Market Capitalization | $2.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Acticor Biotech SAS's assets below their book value (0.22 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Acticor Biotech SAS's assets decreased by 24.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Acticor Biotech SAS (2007–2023)
The table below shows the annual total assets of Acticor Biotech SAS from 2007 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €9.72 Million | -24.93% |
| 2022-12-31 | €12.94 Million | -27.62% |
| 2021-12-31 | €17.88 Million | +62.27% |
| 2020-12-31 | €11.02 Million | -28.46% |
| 2019-12-31 | €15.40 Million | +35.03% |
| 2018-12-31 | €11.41 Million | +448.89% |
| 2017-12-31 | €2.08 Million | -92.73% |
| 2016-12-31 | €28.59 Million | -4.91% |
| 2015-12-31 | €30.07 Million | -4.28% |
| 2014-12-31 | €31.41 Million | -4.50% |
| 2013-12-31 | €32.90 Million | +15.22% |
| 2012-12-31 | €28.55 Million | +32.32% |
| 2011-12-31 | €21.58 Million | +204.36% |
| 2010-12-31 | €7.09 Million | +41.52% |
| 2009-12-31 | €5.01 Million | +41.98% |
| 2008-12-31 | €3.53 Million | +221.90% |
| 2007-12-31 | €1.10 Million | -- |